Genomics|HuGENet|Reviews|Tables|HLA-DPB1 and Chronic Beryllium Disease|PubMed ID: 12615603

HLA-DPB1 and Chronic Beryllium Disease
by Erin C. McCanlies¹, Kathleen Kreiss², Michael Andrew¹ and Ainsley Weston³

Tables

TABLE 1: Frequency of HLA*-DPB1^Glu69 alleles across populations in English-language studies published between 1993 and 2002

Authors and year of publication (ref. no.)	Laboratory method(s)	Study population and/or location (sample size)	HLA-DPB1*02 allele†	Allelic fre-quency‡ (%)	Carrier fre-quency ‡ (%)	Non- HLA-DPB1*02 allele†	Allelic fre-quency ‡ (%)	Carrier fre-quency ‡ (%)
Gao et al., 1991 (25)	PCR*/ dot blot	Northern Chinese (n = 88)	*0201	18		*0601	1
			*0202			*0901	1
			Total	3		*1301	5
				21		*1701	6
						Total	13
Falco et al., 1993 (26)	PCR/ dot blot	Southern Chinese (n = 99)	*0201	15		*1301	11
			*0202	11		*1901	0.5
			Total	26		*2101	6
						Total	18
Lienert et al., 1993 (27)	PCR/ RFLP*	Australia
		Caucasians (n = 50)	*0201	9		*0601	3
						*1001	2
						*1301	2
						*1601	1
						*1701	1
						*1901	1
						Total	10
		Aboriginals-central desert (n = 60)	*0201	32		*0601	0.8
			*0202	4		*1601	18
			Total	36		*2201	2
						Total	21
		Aboriginals-northern coast n = 33)	*0201	17		*1601	8
			*0202	3		*2201	6
			Total	20		Total	14
Titus-Trachtenberg et al., 1994 (28)	SSOP*	Cayapa Indians, Ecuador (n = 100)	*0201	4		*1301	6
Briceno et al., 1996 (29)	SSOP	Colombia
		Kogui (n = 50)
		Arsario (n = 50)
		Ijka (n = 40)
		Wayuu (n = 54)
		Vaupes (n = 46)
		Coreguaje (n = 45)
		Embera (n = 49)				*1301	28
Ploski et al., 1996 (30)	SSOP	Caucasians, Poland (n = 158)	*0201		23	*0601		3
						*0801		1
						*0901		1
						*1001		1
						*1301		3
						*1701		5
						*1901		1
						Total		15
Trachtenberg et al., 1996 (31)	SSOP	Colombia
		Kogui (n = 30)
		Ijka (n = 30)
		Sikuani (n = 28)
		Ingano (n = 11)
		Coreguaje (n = 20)	*0201	2
		Nukak (n = 20)
		Waunana (n = 30)
		Embera (n = 20)				*1301	23
		Tule (n = 29)				*1301	35
Trachtenberg et al., 1996 (32)	SSOP	African-American Colombians
		Cauca (n = 40)	*0201	3		*1301	5
						*1701	5
						Total	10
		Choco (n = 20)	*0201	3		*0901	3
						*3001	3
						Total	6
		Providencia (n = 20)	*0201	10		*1001	3
						*1301	3
						*1601	5
						*1701	8
						Total	19
Just et al., 1997 (33)	SSOP	African Americans, New York City (n = 241)	*0201	10		*0601	1
			*0202	0.4		*0901	0.4
			Total	10		*1301	5
						*1601	0.2
						*1701	9
						*1901	0.2
						*2901	0.4
						*3001	0.4
						Total	17
Cechova et al., 1998 (34)	RFLP	Slovak Republic (n = 146)	*0201	14		*0601	0.3
			*0202	0.3		*1001	0.7
			Total	14		*1001	1.4
						*1601	2
						*1701	1.7
						Total	6
May et al., 1998 (35)	SSOP	Nigeria (n = 130)	*0201	8.5		*1001	0.4
						*1301	2.3
						*1601	3.5
						*1701	4.6
						*3001	0.8
						*3201	0.8
						*4601	0.4
						*5501	0.4
						Total	13
		Liberia (n = 110)	*0201	5		*0601	0.5
						*1301	3.2
						*1701	6.8
						*3001	0.9
						*3701	0.5
						Total	12
		Gabon (n = 120)	*0201	18.3		*1001	0.4
						*0601	1.3
						*1301	0.8
						*1701	2.5
						*1901	1.3
						*2901	0.8
						*3301	0.4
						Total	8
Poulton et al., 1998 (36)	SSOP/ sequencing	Bantu, Cameroon (n = 89)	*0201		35	*1301		6
			*0202		2	*1701		6
			Total		37	*1901		1
						*2901		2
						Total		15
Loudova et al., 1999 (37)	SSOP	Prague, Czech Republic (n = 92)	*0201	11	23	*0901	0.5	1
						*1001	1	2
						*1301	2	4
						*1701		4
						*1901	0.5	1
						Total	6	12
Zimdahl et al., 1999 (38)	SSOP/ sequencing	Asia-Oceana
		Trobriand Islands (n = 81)	*0201	0.6
		Papua New Guinea
		Roro (n = 26)	*0201	10
		Highlands (n = 28)	*0201	27
			*0202	2
			Total	29
		Tolai, New Britain (n = 48)	*0201	57		*1701	2
			*0202	1
			Total	58
		Western Samoa (n = 22)	*0201	2		*4801	2
		Java (n = 59)	*0201	2.6		*0901	20
			*0202	7.6		*1301	20
			Total	10		*1701	1
						*1901	1
						Total	42
		Borneo (n = 21)	*0201	2		*1301	43
		Taiwanese/ Aboriginals: Ami, Atayal, Bunun, Paiwan (n = 48)	*0201	5		*1301	2
						*2201	1
						Total	3

TABLE 2: Prevalence of beryllium sensitization and chronic beryllium disease among beryllium workers in English-language studies published between 1993 and 2002

Authors and year of publication (ref. no.)	Beryllium exposure site surveyed	Sample size	Beryllium sensitization			Chronic beryllium disease
Authors and year of publication (ref. no.)	Beryllium exposure site surveyed	Sample size	No. with test results*	No. sensi-tized	%	No. evaluated†	No. with chronic beryllium disease	%
Kreiss et al., 1989 (63)	Rocky Flats nuclear weapons facility (Denver, Colorado)	51	51	6	11.8	5	4	80
Kreiss et al., 1993 (64)	Coors Ceramics Company (Golden, Colorado)	505	505	8	1.6	8	8	100
Kreiss et al., 1993 (65)	Rocky Flats‡	895	890	17	2	16	13	81
Kreiss et al., 1996 (66)	Brush Wellman, Inc. (Tucson, Arizona)	136	136	8	5.9	7	6	86
Stange et al., 1996 (67)	Rocky Flats§	4,268	4,268	74	1.7	74	27	36
Kreiss et al., 1997 (68)	Brush Wellman, Inc. (Elmore, Ohio)	627	627	59	9.4	47	24	51
Henneberger et al., 2001 (69)	Brush Wellman, Inc. (Tucson, Arizona)¶	151	151	15	9.9	15	8	53

* Number of persons for whom beryllium lymphocyte proliferation test results were obtained.
† Number of persons who underwent complete clinical evaluation.
‡ Does not include persons surveyed by Kreiss et al. in 1989 (63).
§ Includes cases identified by Kreiss et al. in 1989 and 1993 (63, 65).
¶ Includes persons previously surveyed by Kreiss et al. in 1996 (66).

TABLE 3: Frequency of HLA*-DPB1 alleles among beryllium workers with and without chronic beryllium disease in English-language studies published between 1993 and 2002

Authors and year of publication (ref. no.)	Sample size		Allele	Frequency of allele (%)		p value
Authors and year of publication (ref. no.)	Cases	Controls	Allele	Cases	Controls	p value
Richeldi et al., 1993 (19)	33	44	HLA-DPB1^Asp55/Glu56	79	41	0.005
			HLA-DPB1^Glu69	97	27	0.0001
			HLA-DPB1*0201	30	10	0.05
			HLA-DPB1*0401	14	48	0.001
Richeldi et al., 1997 (20)	6	119	HLA-DPB1^Glu69	83	30	0.01
Wang et al., 1999 (21)	20	75	HLA-DPB1^Glu69	95	45	0.001
			HLA-DPB1^V8/H[Y]9/L11†	79§	30§	0.003
			HLA-DPB1 ^{D84/E85/A86/V87}‡	84§	35§	0.004
Saltini et al., 2001 (23)	22	93	HLA-DPB1^Glu69	72§	40§	0.02
Rossman et al., 2002 (24)	25	82	HLA-DPB1^Glu69	84	48	0.03

* HLA, human leukocyte antigen.
† The superscript V8/H[Y]9/L11 represents the amino acid residues valine, histidine [or tyrosine], and leucine at positions 8, 9, and 11 of the HLA-DPB1 gene.
‡ Carrier frequencies.
§ T he superscript D84/E85/A86/V87 represents the amino acid residues aspartic acid, glutamic acid, alanine, and valine at positions 84, 85, 86, and 87 of the HLA-DPB1 gene.

TABLE 4: Prevalence of chronic beryllium disease according to the presence of the HLA*-DPB1^Glu69 allele and employment in machining.†

Presence of HLA-DPB1^Glu69 allele	Employment in machining	No. of cases (n = 6)	No. of controls (n = 121)	Proportion with chronic beryllium disease	95% confidence interval
No	No	0	55	0.00	0.00, 0.06
No	Yes	1	30	0.03	0.00, 0.17
Yes	No	1	24	0.04	0.00, 0.20
Yes	Yes	4	12	0.25	0.07, 0.52

* HLA, human leukocyte antigen.
† Data were obtained from the paper by Richeldi et al. (20).

Page last reviewed: September 30, 2002 (archived document)
Page last updated: October 12, 2007
Content Source: CDC's Office of Public Health Genomics